Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study

Palliative MedicinePublished 1 April 2005

Simon Noble, Ilora Finlay

DOI10.1191/0269216305pm1008oa

Source URL

Citations133

SJR quartileQ1

SJR score1.49

SNIP1.77

TL;DR

The use of long-term low-molecular-weight heparin therapy, first line in the treatment of established VTE in the palliative care setting, is supported.

Abstract

Venous thromboembolism (VTE) is common in patients with terminal cancer. Current treatment practice with warfarin has a high incidence of complications, including bleeding, poor control and recurrent VTE. Long-term low-molecular-weight heparin (LMWH) therapy is safer and more efficacious in this patient group, but there are concerns that daily therapy may have a negative impact on quality of life. A qualitative study was carried out to determine whether LMWH was acceptable in palliative care patients, both in the community and in-patient units. Forty palliative care patients receiving LMWH for VTE were interviewed. Participants found LMWH to be an acceptable intervention, allowing them freedom from blood tests and optimism regarding their care. It was considered a preferable therapy to warfarin, which had a negative impact on participant's quality of life. The findings of this study support the use of LMWH, first line in the treatment of established VTE in the palliative care setting.

Keywords

MedicineHealth Professions

New England Journal of MedicineLow-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

2,490 Citations2003Agnes Lee, Mark N. Levine +9 more

In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding.

View PDF

CHEST JournalAntithrombotic Therapy for Venous Thromboembolic Disease

2,048 Citations2001Thomas M. Hyers, Giancarlo Agnelli +5 more

Abbreviations: APTT 5 activated partial thromboplastin time; DVT 5 deep venousThrombin clotting time; tPA 5 tissue plasminogen activator (alteplase); VTE 5 venous thromboembolism.

Archives of Internal MedicineComparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer

796 Citations2002Guy Meyer, Zora Marjanovic +8 more

These results confirm that warfarin is associated with a high bleeding rate in patients with venous thromboembolism and cancer, and prolonged treatment with low-molecular-weight heparin may be as effective as oral anticoagulants and may be safer in these cancer patients.

PubMedCauses of death in cancer patients.

257 Citations1975Julian L. Ambrus, Clara M. Ambrus +2 more

Causes of death in the year 1970 were analyzed retrospectively on the basis of clinical and pathologic reports of 506 cases in the Roswell Park Memorial Institute and Hospital.

Seminars in Thrombosis and HemostasisAlterations of Hemostasis Associated With Malignancy: Etiology, Pathophysiology, Diagnosis and Management

141 Citations2008Rodger L. Bick

When approaching the patient with malignancy and either hemorrhage or thrombosis, all of the potential defects in hemostasis must be taken into account, defined from the laboratory standpoint, and treated in as precise a manner as possible.

Clinical OncologyThe Prevalence and Associated Variables of Deep Venous Thrombosis in Patients with Advanced Cancer

117 Citations1999Miriam J. Johnson, Michael Sproule +1 more

Deep venous thrombosis was found to be significantly associated with the above variables, but a combined index was of limited clinical application, suggesting repeated small pulmonary emboli may be responsible for more symptoms than previously recognized in cancer patients.

Palliative MedicineHow do palliative physicians manage venous thromboembolism?

45 Citations1997Miriam J. Johnson

Assessment of current practice and perceived problems within the management of venous thromboembolism (VTE) in patients with advanced cancer found that outpatients are more likely to be anticoagulated than inpatients.

Palliative MedicineProblems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin

37 Citations1997Miriam J. Johnson

Low molecular weight heparins are proven to be efficacious in the treatment of VTE, are renally excreted and therefore do not interact with many commonly used concurrent medications and will be used in patients for whom anticoagulation is indicated during a six-month period, after which practice will be again reviewed.

Seminars in Thrombosis and HemostasisLow-Molecular-Weight Heparin or Oral Anticoagulation for Secondary Prevention of Deep Vein Thrombosis in Cancer Patients

5 Citations2003Mark Levine

In order to optimize treatment of acute venous thromboembolism in cancer patients, the following outcomes must be considered: a reduction in the rate of recurrent venousThrombosis, a Reduction in the risk of bleeding compared to that seen with current anticoagulant treatment regimens, and a positive impact on the quality of life of the patient.